نبذة مختصرة : Adverse Drug Reactions (ADRs) have a high impact on morbidity and mortality of the population, becoming a public health issue. Studying and publishing about these is referred as pharmacovigilance. The primary objective of this article is to describe and compare the adverse reactions produced by drugs of nervous system action (CNS-D) and neurological ADRs produced by drugs of systemic action (Sys-D). To further develop the need of reporting adverse reactions. This is an observational, cross-sectional, retrospective study performed on a database of neurological consultations which took place at the Neurology department. Patients meeting the inclusion criteria were selected and divided into two groups: Sys-D and CNS-D. Demographic and neurological variables were analyzed. Parametric and non-parametric statistics were used according to distribution. The Naranjo Algorithm (NA) was used to define causality. 71 ADRs were described, from which 63.38% (n = 45) were produced by CNS-D, especially antiepileptics by 47% (n = 21) and psycholeptics by 44%. Of the total, 36.62% (n = 26) were caused by Sys-D, such as antineoplastics (n = 9) and antibiotics (n = 9), being Cefepime the most frequent. The diagnosis of ADRs caused by a Sys-D was delayed prolonging hospitalization (p 0.05) due to a lower NA score (p 0.003) compared to the CNS-D group. Multiple frequently used drugs of systemic action, such as antineoplastics and antibiotics, generate neurological adverse effects. From our analysis, it was presumed that the suspicion of a neurological ADR caused by these drugs was scarce, thus causing a higher morbidity for the patient. ; Las Reacciones Adversas a Medicamentos (RAM) tienen un alto impacto en la morbilidad y mortalidad de la población, convirtiéndose en un problema de salud pública. El estudio y la publicación de las mismas se denomina farmacovigilancia. El objetivo principal de este artículo es describir y comparar las reacciones adversas producidas por medicamentos de acción sobre el sistema nervioso (SNC-D) y las ...
Relation: Journal of Applied Cognitive Neuroscience; Bignone, I. y Schiaffino, S. (2016). Manual de Buenas Prácticas de Farmacovigilancia. [1a ed.]. Buenos Aires: Ediciones Farmacológicas.; Bolaños, R. (Coord.). (2016). Psicotrópicos y estupefacientes. Buenos Aires: Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. Buenos Aires: ANMAT. Recuperado de http://www.anmat.gov.ar/ssce/Libro-psicotropicos-estupefacientes.pdf; Chaio, S.; Toibaro, J.; Valicenti, P. & Saidón, P. (2013). Reacciones adversas medicamentosas y errores de prescripción: Morbi-Mortalidad. Medicina, 73(2), 111–118. Recuperadode http://www.scielo.org.ar/pdf/medba/v73n2/v73n2a03.pdf; Edwards, R. & Aronson, J. (2000). Adverse drug reactions: definitions, diagnosis, and management. Lancet, 356(9237), 1255–1259. https://doi.org/10.1016/S0140-6736(00)02799-9; Grill, M. F. & Maganti, R. K. (2011). Neurotoxic effects associated with antibiotic use: management considerations. British Journal of Clinical Pharmacology, 72(3), 381–393. https://doi.org/10.1111/j.1365-2125.2011.03991.x; Lazarou, J.; Pomeranz, B. & Corey P. (1998). Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA, 279(15), 1200–1205. https://doi.org/10.1001/jama.279.15.1200; Martino, G.; Rojas, G.; Sánchez, M. P.; Isaa, S.; Bres, M.; Camino, M. V.; Merchán, X.; Aldinio, V.; Parisi, V.; Persi, G.; Pereira, N. & Gatto, E. (2019). Seguridad de fármacos antineoplásicos e inmunomoduladores aplicados a la neurología. Neurolargía Argentina, 11(3), 136–144. https://doi.org/10.1016/j.neuarg.2019.03.001; Naranjo, C. A.; Busto, U.; Sellers, E. M.; Sandor, P.; Ruiz, I.; Roberts E.A.; Janecek, E.; Domecq C. & Greenblatt, D. J. (1981). A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics, 30(2), 239–245. https://doi.org/10.1038/clpt.1981.154; Orta, I. A.; Garcia, O.; Triolet, A. T.; Gómez, C. & Ruiz, K. (2008). Reacciones adversas a medicamentos en una unidad de terapia intensiva. Revista Electrónica de Biomedicina, 2, 10–18. Disponible en http://biomed.uninet.edu/2008/n2/alfonso.html; Ponte, M. L.; Ragusa, M.; Armenteros, C. & Wachs, A. (2013). Relevancia de la farmacovigilancia hospitalaria en la práctica médica actual. Medicina (Buenos Aires), 73(1), 35–38. Recuperado de http://www.scielo.org.ar/pdf/medba/v73n1/v73n1a07.pdf; Rattagan, M. L.; Lisei, D.; Rojas, J. G.; Persi, G.; Parisi, V.; López , M.; Da Prat, G.; Bres M. & Gatto, E. (2016). Uso de psicotrópicos y carga sedativa en pacientes adultos con y sin demencia. Vertex, XXVII(129), 332–338. Disponible en http://www.editorialpolemos.com.ar/vertex129.php; República de Argentina. Ministerio de Salud. (10 de septiembre de 2012). Buenas practicas de farmacovigilancia. [Disposición n° 5358]. Boletín Nacional: 23-Ene-2013. Disponible en https://www.argentina.gob.ar/normativa/nacional/disposici%C3%B 3n-5358-2012-207727; Rojas, G.; Demey, I. & Arizaga, R. L. (2013). Medicamentos utilizados para trastornos cognitivos. Análisis de un millón y medio de prescripciones en la Argentina. Medicina (Buenos Aires), 73(3), 213–223. Recuperado de http://www.scielo.org.ar/pdf/medba/v73n3/v73n3a03.pdf; Sauro, K. M.; Quan, H.; Sikdar, K.; Faris, P. & Jette, N. (2017). Hospital safety among neurologic patients: A population-based cohort study of adverse events. Neurology, 89(3), 284–290. https://doi.org/10.1212/wnl.0000000000004111; VNM. (s.f.). Vademecum Nacional de Medicamentos. Buenos Aires: ANMAT. Disponible en http://anmatvademecum.servicios.pami.org.ar/index.html; WHO. (2010). International Statistical Classification of Diseases and Related Health Problems 10th Revision. Sweden: CDC. Available: http://apps.who.int/classifications/icd10/browse/2010/en; WHO. (1999). Perspectivas políticas de la OMS sobre medicamentos: La farmacovigilancia: garantía de seguridad en el uso de los medicamentos. [WHO/EDM/QSM/99.1]. Ginebra: OMS. Disponible en https://apps.who.int/iris/handle/10665/65892; WHO/Centre for Drug Statistics Methodology. (2021). The Anatomical Therapeutic Chemical (ATC) classification system. [Online]. Available: https://www.whocc.no/atc_ddd_index/; WHO. The Uppsala Monitoring Centre. (2001). Vigilancia de la seguridad de los medicamentos. Guía para la instalación y puesta en funcionamiento de un Centro de Farmacovigilancia. Sweden: UMC. Available: http://www.essalud.gob.pe/ietsi/pdfs/informacion_tecnica/OMS_guia_farmacovigilancia.pdf; 12; Sánchez-de-Paz, M.-P., Da-Prat-de-Magalhaes, G., Isa, S., Aldinio, V., Norberto-Latella, A., Mabel-Gatto, E., & Rojas, G. J. (2021). Pharmacovigilance in Neuroscience: Farmacovigilancia en neurociencia. Journal of Applied Cognitive Neuroscience, 2(1), e00163800. https://doi.org/10.17981/JACN.2.1.2021.04; https://hdl.handle.net/11323/10134; Corporación Universidad de la Costa; REDICUC – Repositorio CUC; https://repositorio.cuc.edu.co/
Processing Request
No Comments.